Connection

Jim Oates to Antibodies, Monoclonal, Humanized

Back to Details
This is a "connection" page, showing publications Jim Oates has written about Antibodies, Monoclonal, Humanized.
Jim Oates
Connection Strength
0.181
Antibodies, Monoclonal, Humanized
  1. Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus. Arthritis Rheumatol. 2022 01; 74(1):112-123.
    View in: PubMed
    Score: 0.181
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.